İmportance of ki 67 value for pathologic complete response in locally advanced breast cancer patients receiving neoadjuvant chemotherapy

Neoadjuvant chemotherapy (NACT) improves overall survival and renders possible breast-conserving treatment in locally advanced breast cancer. Association of Ki-67 and pCR is controversial.181 patients who received neoadjuvant chemotherapy between 2010 and 2017 years, were scanned. We investigated association between Ki-67 levels obtained before NACT and pCRs after NACT. Results : This study was enrolled 157 patients .The median age was 49 (25 –83) in stage 2 group and 52 (23 –76) in stage 3 group.In patients with stage 2 breast cancer(n=108), mean level of Ki-67 was 38,0 (1–90) and in stage 3(n=59), was 35(2 –95). There was no statistically significant correlation between Ki-67 levels and pCR in stage 2 and stage 3 groups (p=0.213, 0.533 respectively). The mean level of Ki-67 in patients with pCR was 33,0and in patients with non-pCR was 41 in stage 2 group. This difference was not statistically significant ( p=0.079). In stage 3 group, the mean level of Ki-67 in patients with pCR was 44 and in patients with non-pCR was 31but this difference was not statistically significant (p=0.236). Conclusion : There was no relation between Ki-67 and pCR in our study but conclusions in literature remain controversial and randomised controlled studies are needed to determine the relation.